无创检测策略分层管理进展性慢性肝病应用研究进展

doi:10.3969/j.issn.1672-5069.2026.01.002

Abstract

Cheng Huan, Wang Haiyu, Shen Guojun, et al. Non-invasive testing strategies in the stratified management of patients with advanced chronic liver disease[J]. Journal of Practical Hepatology, 2026, 29(1): 5-8.

References

[1] Franchis R. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol, 2015, 63(3): 743-752.
[2] Papatheodoridi M, Hiriart J B, Lupsor-Platon M, et al. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. J Hepatol, 2021, 74(5): 1109-1116.
[3] Ji Y, Li J, He Q, et al. Baveno VI elastography criteria for ruling in cACLD works well in patients with MAFLD. J Hepatol, 2021, 75(5): 1243-1245.
[4] Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol, 2022, 76(4): 959-974.
[5] Berzigotti A, Tsochatzis E, Boursier J, et al. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol, 2021, 75(3): 659-689.
[6] Wang K, Lu X, Zhou H, et al. Deep learning radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis in chronic hepatitis B: a prospective multicentre study. Gut, 2019, 68(4): 729-741.
[7] Guglielmo F F, Barr R G, Yokoo T, et al. Liver fibrosis, fat, and iron evaluation with MRI and fibrosis and fat evaluation with US: a practical guide for radiologists. Radiographics, 2023, 43(6): e220181.
[8] Jachs M, Hartl L, Simbrunner B, et al. The sequential application of Baveno VII criteria and VITRO score improves diagnosis of clinically significant portal hypertension. Clin Gastroenterol Hepatol, 2023, 21(7): 1854-1863,e10.
[9] Sterling R K, Asrani S K, Levine D, et al. AASLD practice guideline on noninvasive liver disease assessment of portal hypertension. Hepatology, 2025, 81(3): 1060-1085.
[10] Sanyal A J, Harrison S A, Ratziu V, et al. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials. Hepatology, 2019, 70(6): 1913-1927.
[11] Loomba R, Adams L A. The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH. Hepatology, 2019, 70(6): 1885-1888.
[12] Mattos A A, Mattos A Z, Sartori G D P, et al. The role of elastography in clinically significant portal hypertension. Arq Gastroenterol, 2023, 60(4): 525-535.
[13] Stafylidou M, Paschos P, Katsoula A, et al. Performance of Baveno VI and expanded Baveno VI criteria for excluding high-risk varices in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol, 2019, 17(9): 1744-1755,e11.
[14] Wu CW, Lui RN, Wong VW, et al. Baveno VII criteria is an accurate risk stratification tool to predict high-risk varices requiring intervention and hepatic events in patients with advanced hepatocellular carcinoma. Cancers (Basel), 2023, 15(9): 2480.
[15] Vanderschueren E, Armandi A, Kwanten W, et al. Spleen stiffness-based algorithms are superior to Baveno VI criteria to rule out varices needing treatment in patients with advanced chronic liver disease. Am J Gastroenterol, 2024, 119(8): 1515-1524.
[16] Zhang X, Song J, Zhang Y, et al. Baveno VII algorithm outperformed other models in ruling out high-risk varices in individuals with HBV-related cirrhosis. J Hepatol, 2023, 78(3): 574-583.
[17] Dajti E, Villanueva C, Berzigotti A, et al. Exploring algorithms to select candidates for non-selective beta-blockers in cirrhosis: A post hoc analysis of the PREDESCI trial. J Hepatol, 2025, 82(3): 490-498.
[18] Ma J, Gong X, Luo J, et al. Impact of intrahepatic venovenous shunt on hepatic venous pressure gradient measurement. J Vasc Interv Radiol, 2020, 31(12): 2081-2088.
[19] Dajti E, Ravaioli F, Zykus R, et al. Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysis. Lancet Gastroenterol Hepatol, 2023, 8(9): 816-828.
[20] Jachs M, Sandmann L, Hartl L, et al. Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta. J Hepatol, 2024, 81(2): 248-257.
[21] Mandorfer M, Aigner E, Cejna M, et al. Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV). Wien Klin Wochenschr, 2023, 135(Suppl 3): 493-523.
[22] Celsa C, Veneziano M, Di Giorgio F M, et al. Non-invasive diagnostic tests for portal hypertension in patients with HBV- and HCV-related cirrhosis: a comprehensive review. Medicina (Kaunas), 2024, 60(5): 690.
[23] Villanueva C, Albillos A, Genescà J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 2019, 393(10181): 1597-1608.
[24] Rasmussen D N, Thiele M, Johansen S, et al. Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease. J Hepatol, 2021, 75(5): 1017-1025.
[25] Thorhauge K H, Semmler G, Johansen S, et al. Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease. J Hepatol, 2024, 81(1): 23-32.
[26] Gawrieh S, Vilar-Gomez E, Wilson L A, et al. Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD. J Hepatol, 2024, 81(4): 600-608.
[27] Wang H, Liang W, Zhou L, et al. Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis. Clin Mol Hepatol, 2025[ahead of print].
[28] Semmler G, Alonso López S, Pons M, et al. Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure. J Hepatol, 2024, 81(1): 76-83.
[29] Lens S, Baiges A, Alvarado-Tapias E, et al. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. J Hepatol, 2020, 73(6): 1415-1424.
[30] Semmler G, Lens S, Meyer E L, et al. Non-invasive tests for clinically significant portal hypertension after HCV cure. J Hepatol, 2022, 77(6): 1573-1585.
[31] Shearer J E, Jones R, Parker R, et al. The natural history of advanced chronic liver disease defined by transient elastography. Clin Gastroenterol Hepatol, 2023, 21(3): 694-703,e8.
[32] Gidener T, Ahmed O T, Larson J J, et al. Liver stiffness by magnetic resonance elastography predicts future cirrhosis, decompensation, and death in NAFLD. Clin Gastroenterol Hepatol, 2021, 19(9): 1915-1924,e6.
[33] Higuchi M, Tamaki N, Kurosaki M, et al. Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality. Aliment Pharmacol Ther, 2022, 55(3): 292-301.
[34] Semmler G, Hartl L, Mendoza Y P, et al. Simple blood tests to diagnose compensated advanced chronic liver disease and stratify the risk of clinically significant portal hypertension. Hepatology, 2024, 80(4): 887-900.
[35] Jachs M, Hartl L, Simbrunner B, et al. Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient. J Hepatol, 2024, 80(5): 744-752.

Non-invasive testing strategies in the stratified management of patients with advanced chronic liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Wu Hong, Lyu Chun, Jiang Zhengwei, et al. Clinical feature and prognosis of patients with acute hepatitis E: An analysis of 52 cases [J]. Journal of Practical Hepatology, 2026, 29(1): 41-44.
[2]	Ma Fengjin, Chen Yusheng, Zhou Mingkai, et al. Application of COSSH-ACLF II score and LSR combination for evaluating prognosis of patients with HBV-related acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2026, 29(1): 73-76.
[3]	Zhou Shenghui, Li Qi, Ding Huiguo. Clinical feature and prognosis of patients primary biliary cirrhosis complicated with esophagogastric variceal bleeding [J]. Journal of Practical Hepatology, 2026, 29(1): 105-108.
[4]	Zhu Chaofan, Jia Jing, Wang Dan. Impact of cancerous KK-LC-1 expression on prognosis of patients with hepatocellular carcinoma undergoing target and immunotherapy after hepatectomy [J]. Journal of Practical Hepatology, 2026, 29(1): 125-128.
[5]	Qiu Yaoxue, Sun Yinchun, Chen Cheng, et al. Clinical feature and antibiotic application in patients with bacterial liver abscess: An analysis of 90 cases [J]. Journal of Practical Hepatology, 2026, 29(1): 137-140.
[6]	Zhang Qian, Ding Rong, Ji Wenli. Clinical feature, pathogen distribution and prognosis in patients with pyogenic liver abscess [J]. Journal of Practical Hepatology, 2025, 28(6): 922-925.
[7]	Liu Jiayang, Lu Jun, Li Liang, et al. Clinical feature of patients with IgG4-related sclerosing cholangitis and concomitant autoimmune pancreatitis: An analysis of 19 cases [J]. Journal of Practical Hepatology, 2025, 28(5): 719-722.
[8]	Ju Min, Yang Wei, Ding Xiaoshan, et al. Risk factors of acute liver injury in patients with sepsis: An analysis of 107 cases [J]. Journal of Practical Hepatology, 2025, 28(5): 727-730.
[9]	Wen Wen, Bai Jie, Li Yongguo. Impact of sarcopenic obesity on prognosis of patients with chronic liver diseases [J]. Journal of Practical Hepatology, 2025, 28(4): 481-484.
[10]	Feng Shengju, Zang Yichen, Tong Xiao, et al. Impact of cancerous tissue fatty acid translocase expression on prognosis of patients with hepatocellular carcinoma after hepatectomy [J]. Journal of Practical Hepatology, 2025, 28(4): 633-635.
[11]	Huang Yan, Yang Zhiyong, Huang Qian, et al. Poor prognosis of patients with intrahepatic cholangiocarcinoma with high serum CEA, CA125, CYFRA21-1 and VEGF levels [J]. Journal of Practical Hepatology, 2025, 28(3): 442-445.
[12]	Zhu Tingting, Chen Yiyun, Xie Fanci, et al. Non-invasive assessment of liver fibrosis reverse in patients with chronic liver diseases [J]. Journal of Practical Hepatology, 2025, 28(2): 169-172.
[13]	Guo Jianhui, Zhou Yongbing, He Qin. Changes of serum sST2, TLR4, suPAR and Beclin1 levels in patients with HBV-related acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2025, 28(2): 230-233.
[14]	Li Shiwei, Li Jiaguo, Zhu Jing, et al. Serum ANGPTL2, sVAP-1 and HMGB1 level changes in patients with hepatitis B virus infection-related acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2025, 28(2): 234-237.
[15]	He Pei, Feng Lei, Cao Xianghong, et al. A Meta analysis of correlation of RNA m6A methylation to prognosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2025, 28(2): 254-257.